Alnylam Achieved Full Year 2023 Preliminary Global Net Product Revenues Of $1.241B For ONPATTRO, AMVUTTRA, GIVLAARI, And OXLUMO; December 31, 2023, Co Had Preliminary Cash, Cash Equivalents, And Marketable Securities Of ~$2.4B
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported preliminary global net product revenues of $1.241 billion for the full year 2023, a 39% annual growth, for its products ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. As of December 31, 2023, the company had approximately $2.4 billion in cash, cash equivalents, and marketable securities.
January 08, 2024 | 1:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported a significant 39% growth in annual revenues for 2023, with a robust balance sheet including $2.4 billion in cash and investments.
The reported 39% growth in annual revenues is a strong indicator of the company's financial performance and product success. This positive financial news is likely to instill investor confidence and could lead to a short-term increase in stock price. The substantial cash reserves further underscore the company's financial stability, which is typically viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100